Argos Therapeutics Company Profile (NASDAQ:ARGS)

Analyst Ratings

Consensus Ratings for Argos Therapeutics (NASDAQ:ARGS) (?)
Ratings Breakdown: 7 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $12.57 (139.00% upside)

Analysts' Ratings History for Argos Therapeutics (NASDAQ:ARGS)
Show:
DateFirmActionRatingPrice TargetActions
6/20/2016Piper Jaffray Cos.Reiterated RatingOverweight$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2016Needham & Company LLCReiterated RatingBuy$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016FBR & CoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/19/2016Roth CapitalBoost Price TargetBuy$11.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/30/2016Stifel NicolausLower Price TargetBuy$16.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$17.00 -> $12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$17.00 -> $12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2015MLV & Co.Set Price TargetBuy$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Argos Therapeutics (NASDAQ:ARGS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
5/12/2016Q1($0.56)($0.57)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/29/2016Q4($0.88)($0.84)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/16/2015Q315($0.92)($0.97)$158.35 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2015Q215($0.80)($0.95)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2015Q115($0.80)($0.89)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/30/2015Q314($0.73)($0.83)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014($0.65)($0.77)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2014Q214($0.60)($0.61)$1.27 million$1.26 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q114($0.46)($1.05)$1.26 million$0.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/27/2014($2.63)($36.19)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Argos Therapeutics (NASDAQ:ARGS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.70)($0.54)($0.62)
Q2 20162($0.58)($0.52)($0.55)
Q3 20162($0.70)($0.52)($0.61)
Q4 20162($0.60)($0.51)($0.56)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Argos Therapeutics (NASDAQ:ARGS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Argos Therapeutics (NASDAQ:ARGS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
12/16/2015Andrei Vladimirovich PetrovDirectorBuy5,000$1.80$9,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2015Joan WinterbottomInsiderBuy250$1.83$457.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015Alexey Alexandrovic VinogradovDirectorBuy2,000$2.15$4,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2015Jeffrey D AbbeyCEOBuy1,000$3.89$3,890.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2015Holle Philippe Marie Marce VanDirectorBuy10,000$4.28$42,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2015Holle Philippe Marie Marce VanDirectorBuy12,000$6.27$75,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Holle Philippe Marie Marce VanDirectorBuy5,000$6.26$31,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2015Jean LamarreDirectorBuy2,500$6.14$15,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2015Jeffrey D AbbeyCEOBuy5,500$4.75$26,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2014Deventer Sander VanDirectorBuy36,416$8.00$291,328.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2014International S PharmstandardMajor ShareholderBuy1,275,000$8.00$10,200,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Argos Therapeutics (NASDAQ:ARGS)
DateHeadline
07/29/16 02:34 PMHot Biotech Stocks Recap: Hemispherx Biopharma, Inc. (NYSEMKT:HEB), Argos Therapeutics, Inc. (NASDAQ:ARGS) - The Voice Registrar
07/29/16 02:34 PMCurrent Argos Therapeutics, Inc. (NASDAQ:ARGS) PT Means Stock Is Worth Almost $18 - Review Fortune
07/29/16 05:12 AMARGOS THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statem -
07/28/16 03:35 PMHot Line At Active Movers- Argos Therapeutics (NASDAQ:ARGS), Noble (NYSE:NE), Exxon Mobil (NYSE:XOM) - Seneca Globe
07/28/16 03:35 PMPre-Market Stocks Briefing: Argos Therapeutics Inc(NASDAQ:ARGS), Groupon Inc(NASDAQ:GRPN) - Review Fortune
07/28/16 08:48 AMArgos Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock and Warrants - [at noodls] - DURHAM, N.C., July 28, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) ('Argos'), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies ...
07/27/16 08:20 PMArgos Therapeutics Announces Proposed Public Offering of Common Stock and Warrants - Yahoo Finance
07/27/16 03:28 PMArgos Therapeutics Announces Proposed Public Offering of Common Stock and Warrants - [at noodls] - DURHAM, N.C., July 27, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) ('Argos'), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies ...
07/27/16 03:08 PM4:08 pm Argos Therapeutics announces proposed public offering of common stock and warrants; details not disclosed -
07/23/16 02:33 PMStock Up Nicely This Week: Argos Therapeutics, Inc. (NASDAQ:ARGS) - TGP
07/22/16 07:34 PMStock Soars, Rewards Investors Nicely Today: Argos Therapeutics, Inc. (NASDAQ:ARGS) - Engelwood Daily
07/22/16 02:33 PMIncreased Volatility Noted on Shares of: Argos Therapeutics, Inc. (NASDAQ:ARGS) - Engelwood Daily
07/22/16 02:33 PMIs Argos Therapeutics Inc a Buy? The Stock Rises Again - Press Telegraph
07/21/16 09:43 AMEarnings Focus and Crowd Sourced Sentiment Review for Argos Therapeutics, Inc. (NASDAQ:ARGS) - TGP
07/21/16 09:43 AMArgos Therapeutics Inc (ARGS) Current Analyst Ratings - Fiscal Standard
07/20/16 03:47 PMAfter Today's Huge Increase, Is Argos Therapeutics Inc's Near-Term Analysis Positive? - Press Telegraph
07/19/16 02:34 PMArgos Therapeutics Inc Stock Technicals Hit Weakness - CML News
07/19/16 02:34 PMArgos Therapeutics, Inc. (NASDAQ:ARGS): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/18/16 02:37 PMHow Analysts Feel About Argos Therapeutics Inc (NASDAQ:ARGS)? - Consumer Eagle
07/18/16 07:28 AMTrading Performance and Target Watch for Argos Therapeutics, Inc. (NASDAQ:ARGS) - Press Telegraph
07/17/16 07:18 AMShares Moving Down on the Week: Argos Therapeutics, Inc. (NASDAQ:ARGS) - Engelwood Daily
07/16/16 02:32 PMArgos Therapeutics Incorporated (NASDAQ:ARGS) Shorts Decreased by 2.74% After Short Covering - Consumer Eagle
07/14/16 02:37 PMEye on Stock Volatility for: Argos Therapeutics, Inc. (NASDAQ:ARGS) - Engelwood Daily
07/14/16 02:37 PMArgos Therapeutics (ARGS) Announces Dosing of First Patient in AGS-004 Phase 2 as HIV Treatment - StreetInsider.com
07/14/16 11:28 AMArgos Therapeutics : Announces First Patient Dosed in Stage 2 of Adult Eradication Trial of AGS-004 in the Treatment of HIV
07/14/16 08:28 AMArgos Therapeutics Announces First Patient Dosed in Stage 2 of Adult Eradication Trial of AGS-004 in the Treatment of HIV - [at noodls] - The investigator-initiated Phase 2 trial is designed to evaluate the virologic impact of the combination of the latency-reversing drug, vorinostat, and AGS-004, the company's investigational immunotherapy ...
07/13/16 02:36 PMArgos Therapeutics Incorporated (NASDAQ:ARGS) Shorts Decreased by 2.74% After Short Covering - Press Telegraph
07/13/16 10:40 AMAnalyst Target and Average Rating Watch: Argos Therapeutics, Inc. (NASDAQ:ARGS) - Press Telegraph
07/12/16 02:38 PMArgos Therapeutics Inc Stock Momentum at Critical Inflection Point - CML News
07/12/16 02:38 PMArgos Therapeutics, Inc. (NASDAQ:ARGS) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/11/16 02:34 PMArgos Therapeutics (ARGS) Names Katz CFO - StreetInsider.com
07/11/16 07:36 AMARGOS THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Finan -
07/11/16 07:22 AMWatch List: Argos Therapeutics, Inc. (NASDAQ:ARGS), Veeva Systems Inc. (NYSE:VEEV), KCG Holdings, Inc. (NYSE ... - KC Register
07/11/16 07:00 AMDr. Richard D. Katz Joins Argos Therapeutics as Chief Financial Officer - [GlobeNewswire] - DURHAM, N.C., July 11, 2016-- Argos Therapeutics, Inc., an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer and ...
07/09/16 10:39 AMArgos Therapeutics Incorporated (NASDAQ:ARGS) Short Interest Decreased By 2.74% - Engelwood Daily
07/07/16 02:35 PMA Reversal for Argos Therapeutics Inc Is Not Near. The Stock Declines Again - Engelwood Daily
07/07/16 02:35 PMOption Market: Argos Therapeutics Inc. Risk Hits An Extreme High - CML News
07/06/16 08:19 PMTop Gainers, Losers Manufacturing Sector
07/06/16 07:23 AMShares Dropping Lower in Session: Argos Therapeutics, Inc. (NASDAQ:ARGS) - Telanagana Press
07/05/16 02:33 PMMorning Watch List: Universal Technical Institute, Inc. (NYSE:UTI), Argos Therapeutics, Inc. (NASDAQ:ARGS), NXP ... - KC Register
07/05/16 11:07 AMBuy 5 Attractive Biotechs at Bargain Prices -
07/05/16 07:20 AMShare Performance Recap for: Argos Therapeutics, Inc. (NASDAQ:ARGS) - Press Telegraph
07/05/16 07:20 AMArgos Therapeutics Inc (ARGS) Broker Price Targets For The Coming Week - Fiscal Standard
07/01/16 02:36 PMShares Headed Up in Session: Argos Therapeutics, Inc. (NASDAQ:ARGS) - Telanagana Press
07/01/16 02:36 PMWhat's Ahead for Argos Therapeutics Inc After Today's Huge Increase? - Engelwood Daily
06/30/16 02:41 PMCould Argos Therapeutics Inc Decline After Today's Huge Increase? - Engelwood Daily
06/29/16 07:19 AMARGOS THERAPEUTICS INC Files SEC form 8-K, Other Events -
06/29/16 07:11 AMArgos Therapeutics Announces Closing of $29.8 Million Second Tranche of March 2016 Financing - [at noodls] - DURHAM, N.C., June 29, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) ('Argos'), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies ...
06/28/16 02:49 PMInvestors Alert: Argos Therapeutics, Inc. (NASDAQ:ARGS), BlackBerry Ltd (NASDAQ:BBRY), Caterpillar Inc. (NYSE ... - KC Register
06/28/16 02:49 PMArgos Therapeutics Added to the Russell 2000® Index - GlobeNewswire (press release)

Social

About Argos Therapeutics

Argos Therapeutics logoArgos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company's Arcelis technology platform utilizes biological components from a patient's own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ARGS
  • CUSIP:
Key Metrics:
  • Previous Close: $5.37
  • 50 Day Moving Average: $6.00
  • 200 Day Moving Average: $5.63
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $136.19M
  • Beta: 2.2
  • Current Year EPS Consensus Estimate: $-1.74 EPS
  • Next Year EPS Consensus Estimate: $-1.64 EPS
Additional Links:
Argos Therapeutics (NASDAQ:ARGS) Chart for Saturday, July, 30, 2016